Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer
Current treatments for men with castration-resistant prostate cancer (CRPC) include the next-generation androgen receptor-targeting agents abiraterone acetate and enzalutamide, cytotoxic drugs docetaxel and cabazitaxel, immunotherapy sipuleucel-T, and radionuclide radium-223 dichloride. For men with bone metastases, the supportive bone-targeting agents zoledronic acid or denosumab are also commonly administered, although these do not improve survival. Newer treatments that aim to target specific genomic aberrations are in late-stage clinical testing. In this chapter, current and emerging treatments across the spectrum of CRPC will be reviewed, including relevant limitations and future directions from late-phase trials.
- Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563–71.CrossRefPubMedCentralGoogle Scholar
- Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol. 2017;35(28):3198–3206.CrossRefPubMedCentralGoogle Scholar
- James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.CrossRefPubMedCentralGoogle Scholar
- Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012;72(9):2176–82.CrossRefPubMedCentralGoogle Scholar
- Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148–59.CrossRefPubMedCentralGoogle Scholar
- van Soest RJ, de Morree ES, Kweldam CF, de Ridder CM, Wiemer EA, Mathijssen RH, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur Urol. 2015;67(6):981–5.CrossRefPubMedCentralGoogle Scholar